Together, these results suggest that the chemotherapy resistance of hypoxic cancer cells due to ATAD2 protein degradation is triggered by the inactivation of 2-OGDD and mediated by the proteasome pathway independent of HIFs and pVHL (Figure 4). This evidence concerns the gene ATAD2 and cancer.